Ülo Leppik

Ilo Elmar Leppik is a neurologist, author, and academic. He is a professor at the University of Minnesota.

Leppik's research interests have included epilepsy, neuropharmacology, and electroencephalography. He is a recipient of the Penfield Award for Excellence from the Montreal Neurological Institute and Hospital and the William Lennox Award from the American Epilepsy Society. He served as the president of the American Epilepsy Society in 1994.

Education Leppik earned a B.Sc. in chemistry from Haverford College in 1964, followed by an M.D. from the University of Pennsylvania in 1968.

Career Leppik began his academic career at the University of Minnesota as an assistant professor of neurology in 1976 and was promoted to associate professor in 1980. In 1986, he was appointed clinical associate professor of pharmacy and later became professor of neurology in 1987, a role he held until 1989. From 1989, he worked as an adjunct professor of neurology and, from 2004, as a professor of pharmacy at the University of Minnesota. He was president of the Central Society for Neurological Research from 1991 to 1992

Research Leppik's research has focused on clinical epilepsy, antiepileptic pharmacology, and the management of seizures in older adults. His worked on epilepsy in aging populations, addressed treatment efficacy, studied age-dependent mortality in status epilepticus, examined diagnostic challenges, and prescribing patterns of anticonvulsant medications. He conducted clinical trials evaluating the safety of antiepileptic drugs and outlined standard diagnostic and treatment approaches in his book Contemporary Diagnosis and Management of the Patient with Epilepsy. Additionally, he developed a cyclodextrin-based injectable formulation of carbamazepine. Based on a rat study with Sherwin, he also reported no potentiation of anticonvulsant activity between phenobarbital and diphenylhydantoin.

Leppik's pharmacoepidemiologic studies have documented the use of older antiepileptic drugs in the elderly, examined nursing-home populations, highlighting increased epilepsy prevalence, and addressed polypharmacy and drug-interaction risks, particularly those associated with phenytoin. His work also contributed to the evaluation of medical cannabis in epilepsy, including policy development in Minnesota and consideration of veterinary applications. Furthermore, in epilepsy management, he identified antiepileptic drugs with stable clearance, limited enzyme interactions, and low neurotoxicity as preferable options.

Awards and honors 1975 – Fellow, Montreal Neurological Institute and Hospital 1975 – Penfield Award for Excellence, Montreal Neurological Institute and Hospital 2007 – William Lennox Award, American Epilepsy Society 2007 – Ludvig Puusepa Medal, Estonian Neurological Society